Manager TitleAgeSince
President - 2023-12-13
Corporate Officer/Principal 57 -
Corporate Secretary - -
Director TitleAgeSince
Director/Board Member 57 2023-12-13
Director/Board Member - 2023-12-13
Date Insider Type Main position Quantity % Market Cap. Importance
12/14/23 Issuer sale

Director

127,934 0.0678%
12/14/23 Issuer sale

Chief Executive Officer

643,595 0.3411%
12/14/23 Issuer sale

Director

97,934 0.0519%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%+4.77% - - 43.15B
-0.21%-4.43%+44.40%+74.13% 66.22B
-3.69%-0.13%+6.82%+68.02% 55.2B
+0.21%+3.44%+11.54%+90.66% 52.79B
+3.28%+5.58%+26.51%+50.05% 45.53B
+0.51%+9.95%+22.40%+133.92% 43.94B
-1.15%+0.39%+263.21%+594.60% 41.64B
+0.10%+9.90%+16.11%+59.33% 34B
-8.38%-6.95%+26.35%-1.93% 25.84B
-0.38%+2.85%+35.47%+25.47% 23.51B
Average -0.98%+4.07%+50.31%+121.58% 43.19B
Weighted average by Cap. -0.72%+3.72%+49.24%+125.91%
Logo Seagen Inc.
Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit : - ventes de produits (87%) ; - royalties (8,4%) ; - revenus issus d'accords de collaboration et de licence (4,6%).
Employees
3,256
  1. Stock Market
  2. Stocks
  3. SGEN Stock